Skip to content

ViralLoop

Your next post already worked.

←

Write from this board Add posts Share

AllXLinkedInInstagramTikTok

FilterOrderGridTableSelect

Loading the board

AbbVie — how they publish

Remix this board

10 posts · curated by ViralLoop

79 posts from @abbvie, Apr 2026 to Sep 2026: a typical post earns 3 likes and 1 reply. That is more than 29% of the 275 other S&P 500 companies we hold content for. About 1 in 5 of their posts opens with a number. Posts with an image or video earn a median of 5 likes (44 posts); text alone 1 like (35). Aug 2026 landed best: a median of 6 likes.

AllX LinkedIn Instagram TikTok

We announced a $1.4B investment to build a new pharmaceutical manufacturing site in Durham, N.C., creating 734 new jobs & progressing against our $100B commitment to U.S. R&D and capital investment, including manufacturing, over the next decade. Read more: t.co

On-screen text reads, "We’re investing $1.4B to build a new manufacturing campus in Durham, N.C. This marks the latest progress in our $100B commitment to U.S. R&D and capital investments, including manufacturing, over the next decade. Construction is expected to be completed by the end of 2028."

Opens with a number

379 likes16 repliesIn reviewGeneralX4mo ago

We've signed a definitive agreement to acquire Apogee Therapeutics. The proposed acquisition will deepen our #immunology portfolio with differentiated assets focused on dermatologic, respiratory and other related inflammatory diseases. Learn more: t.co

Opens with an observation

15 likes2 repliesIn reviewGrowthX2mo ago

JUST IN: The @EU_Commission has approved our treatment for adult and adolescent patients with non-segmental #vitiligo who are candidates for systemic therapy. Read more: t.co

Opens with an observation

12 likes1 repliesIn reviewGeneralX1mo ago

Our Q2 2026 #FinancialResults are in. See them here: t.co $ABBV #earnings

Opens with a number

10 likes5 repliesIn reviewGeneralX1mo ago

NEWS: The @EU_Commission has granted marketing authorization of our medicine as part of a combination regimen for adults with relapsed/refractory (R/R) follicular #lymphoma (FL), developed with @Genmab. Read more: t.co

Opens with an observation

10 likes2 repliesIn reviewMarketingX2mo ago

NEWS: We shared topline results from our Phase 3 trial in adult patients with relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL), in partnership with @Genmab. Learn more: t.co

Opens with an observation

9 likes1 repliesIn reviewScienceX2mo ago

NEWS: The @EU_Commission has approved our treatment for adult and adolescent patients with severe #AlopeciaAreata. Learn more: t.co

Opens with an observation

8 likes1 repliesIn reviewGeneralX1mo ago

NEWS: The @EMA_News #CHMP shared a positive opinion for our investigational treatment in non-segmental #vitiligo. Read more: t.co

Opens with an observation

8 likes1 repliesIn reviewGeneralX2mo ago

#DYK migraine can affect education, relationships, mental health, and work? That’s why we invest in neuroscience research to better support people living with migraine. Learn more about our focus area: t.co #EAN2026

Opens with a question

8 likes1 repliesIn reviewScienceX2mo ago

JUST IN: The @EU_Commission has approved our treatment for children and adolescents aged 6 and older with moderate-to severe #PlaquePsoriasis. Read more: t.co

Opens with an observation

7 likes1 repliesIn reviewGeneralX2mo ago

Boards are how ViralLoop learns your taste — save posts you admire, and turn the collection into content that sounds like you.

Start your own board

AbbVie — how they publish · ViralLoop